The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
Abstract
Background & aims Around 10-20% of patients with non-alcoholic fatty liver disease (NAFLD) are non-obese. The benefit of weight reduction in such patients is unclear. We aim to study the efficacy of lifestyle intervention in non-obese patients with NAFLD and to identify factors that predict treatment response.Methods A total of 154 community NAFLD patients were randomised to a 12-month lifestyle intervention programme involving regular exercise, or to standard care. The primary outcome was remission of NAFLD at Month 12 by proton-magnetic resonance spectroscopy. After the programme, the patients were prospectively followed until Year 6. The Asian body mass index (BMI) cut-off of 25 kg/m 2 was used to define non-obese NAFLD.Results Patients were assigned to the intervention (n = 77) and control (n = 77) groups (39 and 38 in each group had baseline BMI <25 and ≥25 kg/m 2, respectively). More patients in the intervention group achieved the primary outcome than the control group regardless of baseline BMI (non-obese: 67% vs. 18%, p <0.001; obese: 61% vs. 21%, p <0.001). Lifestyle intervention, lower baseline intrahepatic triglyceride, and reduction in body weight and waist circumference were independent factors associated with remission of NAFLD in non-obese patients. Half of non-obese patients achieved remission of NAFLD with 3-5% weight reduction; the same could only be achieved in obese patients with 7-10% weight reduction. By Year 6, non-obese patients in the intervention group remained more likely to maintain weight reduction and alanine aminotransferase normalisation than the control group.Conclusions Lifestyle intervention is effective in treating NAFLD in both non-obese and obese patients. Weight reduction predicts remission of NAFLD in non-obese patients, but a modest weight reduction may be sufficient in this population.Lay summary Some patients with non-alcoholic fatty liver disease (NAFLD) are non-obese. The optimal management of such patients is unclear. In this long-term follow-up study of a clinical trial, we show that remission of NAFLD can be achieved in 67% of non-obese patients after lifestyle intervention. The majority of patients can achieve NAFLD remission with modest weight loss of 3-10%. Non-obese patients are also more likely than obese patients to maintain weight reduction and normal liver enzymes in the long run.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In an RCT of a 12month lifestyle intervention programme, a 3-5% weight reduction led to remission of MASLD (measured by 1 H-MRS) among 50% of the individuals without obesity.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [333]
In the citing paper
“Moreover, individuals de fi ned as non-obese were more likely than individuals with obesity to maintain weight reduction and normal liver enzymes over long-term (6-year) follow-up. 333”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [333]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,146
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Long-term weight loss maintenance
Wing, R. R., & Phelan, S. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.1.222s · Cited by 1,941
Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 319
Portal Hypertension after Liver Transplantation—Causes and Management
Unger, L. W., Mandorfer, M., & Reiberger, T. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00450-8 · Cited by 7
Taming fatty liver: can taurine combat metabolic dysfunction in MASLD?
Meng, L., Lu, F., Zhang, B., Ma, Y., & Gao, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02439-x · Cited by 6
Chen, J., Wang, S., Xin, X., & Xie, J. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04517-3 · Cited by 7
Sun, Z., Liu, M., Guo, J., Wang, S., & Jin, H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.009 · Cited by 6
Kenger, E. B., Guveli, H., Ergün, C., Kaya, E., & Yilmaz, Y. (2020) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2020.0004 · Cited by 6
Wu, N., Zhai, X., Yuan, F., Li, J., Li, D., Wang, J., Zhang, L., Shi, Y. Y., Ji, G., He, G., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1026725 · Cited by 6
Lü, B., Sun, J., Chen, L., Song, X., Deng, Y., Dong, Y., Dong, J., Du, P., Ge, J., Guo, Y., et al. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.01.003 · Cited by 6
Lee, H. A., Moon, H., Kim, Y., Lee, H. A., & Kim, H. Y. (2023) · Trials · doi:10.1186/s13063-023-07444-4 · Cited by 6
Chen, Z., Tang, W., Feng, N., Lv, M., Meng, F., Wu, H., Zhao, Y., Xu, H., Dai, Y., Xue, J., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104912 · Cited by 6
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Chun, H. S., & Lee, M. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0061 · Cited by 6
Kong, A. P. S., Lau, E. S. H., Chun Kwan, O., Luk, A. O. Y., Yip, T. C., Chow, E., Kwok, R., Lee, H. W., Wong, G. L., Ronald, C. W., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110825 · Cited by 6
Hahn, J. W., Lim, J. G., Lee, K. J., Moon, J. S., Kim, T. H., Son, Y., Yon, D. K., Lee, Y. J., Seo, Y., Park, J.-H., et al. (2026) · Gut Pathogens · doi:10.1186/s13099-026-00798-5 · Cited by 5
Zhang, W., Li, M.-Y., Li, Z., Diao, Y., Liu, X.-K., Guo, H.-W., Wu, X.-C., Wang, H., Wang, S., Zhou, Y.-H., et al. (2024) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2024.07.089 · Cited by 5
Heitmann, J., Frings, V. G., Geier, A., Goebeler, M., & Kerstan, A. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14425_g · Cited by 5
Hasegawa, Y., Okada, H., Nakajima, H., Kitagawa, N., Okamura, T., Majima, S., Senmaru, T., Ushigome, E., Nakanishi, N., Nakahata, Y., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13989 · Cited by 5
Han, X., Kong, J., Zhang, H., Zhao, Y., Zheng, Y., & Wei, C. (2024) · Obesity Facts · doi:10.1159/000536447 · Cited by 5
Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis
Schattenberg, J. M. (2020) · Visceral Medicine · doi:10.1159/000507231 · Cited by 5
Impact of lifestyle interventions on pathogenesis of nonalcoholic fatty liver disease
Ezzat, W. M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i20.2633 · Cited by 5
Li, Y., Ji, H. L., Tian, F., Ge, X., Cao, L., & Ma, X. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04038-z · Cited by 4
New Names, New Drugs, Better Outcomes in Steatotic Liver Disease
Peverelle, M., Mbelle, M., & Joshi, D. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0655 · Cited by 4
Husaema, M., Saleh, L. M., Naiem, M. F., Wahyu, A., & Darmawansyah, D. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1739931 · Cited by 4
Маратовна, Б. Р., Dicheva, D. T., Расимовна, Х. А., Андреев, Д. Н., Киримовна, К. А., Евгеньевна, Б. О., Golovkina, N. L., & Maev, I. V. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-563 · Cited by 4
Lindstad, T. M., Pourteymour, S., Lee-Ødegård, S., Drevon, C. A., & Norheim, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072941 · Cited by 4
Chen, J., Gong, P., & Xie, J. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.08.090 · Cited by 8
Li, X., Zhou, W., & Hu, G. (2024) · BMC Public Health · doi:10.1186/s12889-024-18578-8 · Cited by 4
Li, Z., Wang, L., Tian, C., Wang, Z., Zhao, H., Yao, Q., Chen, W., Wuyun, Q., Amin, B., Lian, D., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002179 · Cited by 4
Soni, J., Pathak, N., Gharia, M., Aswal, D., Parikh, J., Sharma, P., Mishra, A., Lalan, D., & Maheshwari, T. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i1.101630 · Cited by 4
Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
Hartl, L., Elias, J., Prager, G., Reiberger, T., & Unger, L. W. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i19.2281 · Cited by 4
Razouki, Z. A., Zhang, X., Hwang, J. P., & Heredia, N. I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154260 · Cited by 4
Yabe, Y., Chihara, K., Oshida, N., Kamimaki, T., Hasegawa, N., Isobe, T., & Shoda, J. (2023) · Nutrients · doi:10.3390/nu15122764 · Cited by 4
Fatty liver disease in living liver donors: a single‐institute experience of 220 donors
Wen, F., Noda, M., Gotoh, K., Morooka, Y., Noda, T., Kobayashi, S., Doki, Y., Eguchi, H., & Umeshita, K. (2021) · Transplant International · doi:10.1111/tri.14005 · Cited by 4
Saidi, A. N., Konings, L. A. M., Dietvorst, C. A. W., de Jong, V., Brouwer, W. P., van der Lelij, A., Alings, M., van Wenum, M., Rauh, S. P., Xu, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70071 · Cited by 5
Cobbold, J. F., Miller, H., Hallsworth, K., Manousou, P., Marjot, T., Allison, M. E. D., Anstee, Q. M., Armstrong, M., Avery, L., Azzu, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00077-4 · Cited by 3
Non-alcoholic fatty liver disease in people with normal body weight
Туркина, С. В., Андреевна, Т. И., & Титаренко, М. Н. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-36-48 · Cited by 3
Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions
Choudhuri, G., Shah, S., Kulkarni, A. V., Jagtap, N., Gaonkar, P. P., Desai, A. S., & Adhav, C. V. (2023) · Cureus · doi:10.7759/cureus.42852 · Cited by 4
Eshraghian, A., Taghavi, S. A., Nikoupour, H., Nikeghbalian, S., & Malek‐Hosseini, S. A. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02781-9 · Cited by 2
Mu, W.-J., Chen, M., Zhu, J., Luo, H.-Y., Li, Y., Li, S., Yan, L.-J., Li, R., & Guo, L. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250242 · Cited by 2
Dai, J., Zhang, S., Shi, J., & Zhu, J. (2025) · Natural Product Communications · doi:10.1177/1934578x251403971 · Cited by 2
Kobayashi, T., Yoneda, M., Duseja, A., Fan, J.-G., Nersesov, A., & Nakajima, A. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.010 · Cited by 3
Kurhaluk, N., Mazur, Z., Kołodziejska, R., & TKACZENKO, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083511 · Cited by 5
MAFLD/MASLD: Past, Present, and Future
Wong, V. W. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70619 · Cited by 2
Lara, C., López-Bermudo, L., Gómez, M. F., Cornejo, A., Berná, G., & Romero‐Gómez, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00019-7 · Cited by 3
Ferri, S., Stefanini, B., Minguzzi, M., Leoni, S., Capelli, R., Secomandi, A., Chen, R., Abbati, C., Santangeli, E., Mattarozzi, K., et al. (2023) · Nutrients · doi:10.3390/nu15061445 · Cited by 2
Sae-lee, K., Surangsrirat, D., Parlawong, C., Anawilkul, T.-T., Assawachamrun, N., Boonbandan, P., Ladapongpuwat, P., Chupetch, B., Thongchai, S., Pruphetkaew, N., et al. (2023) · JMIR Formative Research · doi:10.2196/45298 · Cited by 2
Navarro‐Masip, È., Petit, N. M., Salinas‐Roca, B., Herrerías, F., Vilardell, F., de la Fuente, M. C., Pallarés, J., Santamaría, M., Zorzano-Martínez, M., Sánchez, E., et al. (2024) · Obesity Facts · doi:10.1159/000538765 · Cited by 2
Орлова, С. В., Vodolazkaya, A. N., Tarasova, O., Никитина, Е. А., Prokopenko, E. V., Balashova, N. V., Minosyan, I. S., & Urazov, V. V. (2024) · Medical alphabet · doi:10.33667/2078-5631-2024-16-13-18 · Cited by 3
Yang, J., Tian, C., Liu, M., Guo, H., Lin, F., Ding, Y., Yao, W.-T., Zhang, J., Fan, J., Yu, C., et al. (2024) · Nutrients · doi:10.3390/nu16234212 · Cited by 2
Research Progress on the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
高, 志. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441142 · Cited by 2
Editorial for the Bibliometric-enhanced Information Retrieval Workshop at ECIR 2014
Mayr, P., Schaer, P., Scharnhorst, A., & Mutschke, P. (2014) · arXiv (Cornell University) · doi:10.48550/arxiv.1404.7099 · Cited by 2
Njei, B. M., Ameyaw, P. A., Al‐Ajlouni, Y. A., Njei, L., & Boateng, S. (2024) · Research Square · doi:10.21203/rs.3.rs-3940574/v1 · Cited by 2
Huang, Z., Wei, D., Yu, X., Huang, Z., Lin, Y. B., Lin, W., Su, Z., & Jiang, J. (2023) · Medicine · doi:10.1097/md.0000000000032922 · Cited by 1
Ramírez-Mejía, M. M., Martínez‐Sánchez, F. D., Córdova‐Gallardo, J., & Méndez‐Sánchez, N. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i4.105254 · Cited by 1
Optimizing hepato-metabolic health with lifestyle modifications: A comprehensive review
Agarwal, V., Das, S., Choudhury, A., Meher, D., Sahoo, D., & Sahu, S. K. (2025) · Journal of Integrative Medicine and Research · doi:10.4103/jimr.jimr_78_24 · Cited by 1
Peng, X., Wei, Z., Liu, S., Liu, L., Jiang, H., Yu, L., Xu, X., & Gu, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-96848-0 · Cited by 1
Chen, S. J., Xu, D., Hu, D. K., Hu, P. J., & Huang, T. (2025) · JMIR Medical Informatics · doi:10.2196/75747 · Cited by 1
Li, M., Li, H., Zou, J., Li, R., Zhang, H., Yang, W., Wu, X., & Sun, C. (2025) · Food & Function · doi:10.1039/d5fo04199f · Cited by 1
Bulatova, I. A., Shevlyukova, T. P., Gulyaeva, I. L., Yusupova, A. A., & Trofimova, E. S. (2026) · Perm Medical Journal · doi:10.17816/pmj43135-45 · Cited by 1
Lu, M., Zhang, H., Zhu, X., Xu, J., Xiang, L., Hu, Y., Sun, J., Mai, J., & Ding, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782232 · Cited by 1
Metabolic dysfunction-associated steatotic liver disease in Asia: implications on management
Lai, K. N., & Wong, V. W. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-167 · Cited by 1
Lifespan approaches for the prevention and management of steatotic liver disease
Zelber‐Sagi, S., Ivancovsky-Wajcman, D., Kugelmas, C., Weinstein, A. A., Wong, V. W., Castéra, L., Moore, J. B., Mouzaki, M., Hallsworth, K., Paik, J. M., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01198-5 · Cited by 1
Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
Praveen Sandeep Raj, R., John, R., Manoharan, F., Janeela, A. M., Goel, A., & Kapoor, N. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102107 · Cited by 5
Wang, Z., Li, Z., Tian, C., Yu, C., Chen, X., Sun, Y., Chen, W., Wang, D., Wang, L., Lian, D., et al. (2026) · BMC Surgery · doi:10.1186/s12893-026-03747-w · Cited by 2
Plauth, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00004-5 · Cited by 1
Enfermedad hepática grasa no alcohólica en personas no obesas: revisión narrativa de la literatura
Castro-Sánchez, S., Pérez-Giraldo, E., Restrepo-Gutiérrez, J., & Builes-Montaño, C. (2021) · Hepatología · doi:10.52784/27112330.129 · Cited by 1
A Recent Research on Non Alcoholic Fatty Liver Disease
(2019) · International Journal of Recent Technology and Engineering (IJRTE) · doi:10.35940/ijrte.d1151.1284s219
NAFLD, the hepatic manifestation of the metabolic syndrome
Chaudhury, T., Brodosi, L., Marchesini, G., Mitra, S. K., & Petroni, M. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00055-4 · Cited by 1
Bisseling, T. M., van der Marel, S., Boleij, A., Bruggeling, C. E., & van Meeteren, M. W. (2022) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2761-4_7 · Cited by 1
Diabetes and Non‐alcoholic Fatty Liver Disease
Mantovani, A., Targher, G., & Byrne, C. D. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch57 · Cited by 1
Li, X., Shen, X., & Li, H. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0784 · Cited by 1
Reply to: “NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter”
Wong, V. W., & Chan, H. L.-Y. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.008
Irie, K., Azuma, T., Yonenaga, T., Hada, M., Watanabe, K., Deguchi, F., Obora, A., Kojima, T., & Tomofuji, T. (2020) · Acta Scientifci Nutritional Health · doi:10.31080/asnh.2020.04.0787
Hu, S., Li, X., Sun, Y., Wu, S., Lan, Y., Chen, S., wang, Y., Liao, W., wang, X., Zhang, D., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3920905
Suicide attack: weapon of the weak or crime against humanity?
Ali, M. Y. (2009)
Nonalcoholic Fatty Liver Disease in Lean Chinese: The Public Health Crisis We Can No Longer IgnorePreprint
Deng, P., Weng, L., Li, Y., Wang, J., Li, F., Chen, Z., Wang, J., Yang, Y., Tang, H., Zhu, L., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4055318
Bisseling, T. M., van der Marel, S., Boleij, A., Bruggeling, C. E., & van Meeteren, M. W. (2020) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2324-1_7
Pydyn, N., & Kotlinowski, J. (2022) · Postępy Biochemii · doi:10.18388/pb.2021_446
NAFLD – Prävention und ernährungsmedizinische Behandlungsmöglichkeiten
Roeb, E. (2022) · Ernährung & Medizin · doi:10.1055/a-1917-8335
Metabolic-associated fatty liver disease: pharmacological management
Shi, Y., & Fan, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00010-0
Approaches in the Nutritional Management of Non Alcoholic Fatty Liver Disease
Suryavanshi, A., Sumar, A. I., Rathod, S. B., Rathod, S. B., & Rajbhar, K. (2023) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-8677
Clinical and metabolic aspects of non-alcoholic fatty liver disease depending on BMI
Герасименко, О. Н., Znakharenko, E. A., Михайловна, Г. А., Толмачева, А. А., & Bazueva, А. S. (2023) · Ateroscleroz · doi:10.52727/2078-256x-2023-19-2-154-161
MASLD – Prävention und ernährungsmedizinische Behandlungsmöglichkeiten
Roeb, E. (2023) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2145-0934
Are dairy products the answer to metabolic dysfunction-associated fatty liver disease?
Lau, K. C.-H., & Wong, V. W. (2024) · Hepatology International · doi:10.1007/s12072-024-10655-9
Zhu, X., Wang, H., Zhang, H., Nie, G., Yan, J., & Li, X. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/7081486
Ali, H. H. (2024) · Academic Science Journal · doi:10.24237/asj.02.01.661b
Prabakar, S., Mythili, K., Kiruthikha, M., Abinaya, A., Deepa Sri, S., & Navina, K. (2024) · International Conference on Artificial Intelligence and Machine Learning Applications Theme: Healthcare and Internet of Things (AIMLA) · doi:10.1109/aimla59606.2024.10531483
Gaurav, A., & Iqubal, M. S. (2024) · International journal of life sciences, biotechnology and pharma research. · doi:10.69605/ijlbpr_13.6.29
Lean NAFLD: Prevalence, risk factors/pathogenesis, natural history, and treatment
Ito, T., & Takahashi, H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00001-7
Current Standards in Therapeutic Management
Pustjens, J., & Brouwer, W. P. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_9
The significance of metabolism-associated steatotic liver disease and its treatment
Vašura, A., Machytka, E., Bužga, M., Macháčková, J., & Král, J. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.005
Zabotina, E. E., Khabarova, Y. A., & Stukova, N. Y. (2025) · Experimental and Clinical Gastroenterology · doi:10.31146/1682-8658-ecg-229-9-96-109
Chen, S. J., Xu, D., Hu, D. K., Hu, P. J., & Huang, T. (2025) · doi:10.2196/preprints.75747
Effects of Lifestyle Interventions on Metabolic Dysfunction-Associated Steatotic Liver Disease
Sharma, A. R., & Barb, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_10
Wang, J., Wang, J.-Y., Sun, P.-Q., Wang, X., Yuan, Z., Cao, Q., Pan, S., & Jiang, Y. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i5.103852
Features of Management of Patients with NAFLD and Sarcopenia
Стаценко, М. Е., Myazin, R. G., Ustinova, M. N., & Тумаренко, А. В. (2025) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2025-15-3-178-186
A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD
Razzak, I. A., Razzak, I. A., Noureddin, M., & Trivedi, H. D. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002210 · Cited by 1
AGE-RELATED FEATURES OF LIVER CHANGES DURING INTERMITTENT FASTING (LITERATURE REVIEW)
Kryvozub, D., Riabenko, T. V., & Ponyrko, A. (2025) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2025;13(2):352-363
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3662
Deviation From Genetically Predicted BMI and All‐Cause Mortality: A Cohort Study in the UK Biobank
Zilhäo, N. R., Zhang, J., Boomsma, D. I., Sørensen, T. I. A., & Dahm, C. C. (2025) · Obesity · doi:10.1002/oby.70042
Kato, K., Jojima, T., Tanuma, D., Suda, K., Sakurai, S., Iijima, T., Tomaru, T., Usui, I., & Aso, Y. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100839 · Cited by 1
Metadata
- Authors
- Wong, V. W.-S., Wong, G. L.-H., Chan, R. S.-M., Shu, S. S.-T., Cheung, B. H.-K., Li, L. S., Chim, A. M.-L., Chan, C. K.-M., Leung, J. K.-Y., Chu, W. C.-W., Woo, J., & Chan, H. L.-Y.
- Affiliations
- Chinese University of Hong Kong (HK)
- Corresponding author
- Chan, Henry Lik-Yuen
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 69
- Issue
- 6
- Pages
- 1349-1356
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2888552653
- Cited by
- 319
- References
- 35
- Citations by year
- 2026: 27 · 2025: 39 · 2024: 62 · 2023: 54 · 2022: 40 · 2021: 45 · 2020: 31 · 2019: 18 · 2018: 1
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, non-obese patients, lifestyle intervention, physical activity, weight loss, intrahepatic triglyceride, waist circumference, predictors of treatment response, community-based patients, long-term follow-up, weight maintenance, 1H NMR
- MeSH terms
- Adult, Aged, Diet, Female, Follow-Up Studies, Humans, Life Style, Male, Middle Aged, Obesity, Prospective Studies, Remission Induction, Triglycerides, Weight Loss, Exercise, Body Mass Index, Single-Blind Method, Treatment Outcome, Waist Circumference, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review